secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001077183-24-000052
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q1 revenue up 14% to $156M; Adjusted EBITDA turns positive at $3M
-----------------------------------------------------------------------------

- Clinical Services revenue rose 17% to $135M; test volume up 5% YoY, revenue per test up 11% to $447.
- Advanced Diagnostics revenue declined 3% to $22M; consolidated net loss narrowed 12% to $27M.
- Adjusted EBITDA was $3M, a $10M improvement from -$7M in Q1 2023; cash and equivalents at $385M.
- FY 2024 guidance reaffirmed: revenue $650M-$660M (10-12% growth), Adjusted EBITDA $21M-$24M.
- CEO Chris Smith cited solid execution, NGS adoption growth, and consecutive revenue-per-test improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718324000052/0001077183-24-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718324000052/neo-20240430.htm
  HTML page:      https://secwatch.observer/filing/0001077183-24-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer